NewsSource: EClinCloud

No Sci-Tech Innovation, No Future! Yangtze River Delta Jujin Sci-Tech Innovation Competition Concludes; EClinCloud Clinical Evidence Support Cloud Platform Wins Award

4 min readEClinCloud Editorial Team
Article image

Source: EClinCloud.

Article image

Igniting the engine of development with the spark of science and technology

Answering the call of the times with the power of innovation

No sci-tech innovation, no future

This is a large-scale sci-tech innovation competition

and also a dialogue between sci-tech innovators, management scholars, and industry experts

empowering through management and sci-tech innovation

to infuse China's surging economy with unstoppable sci-tech innovation momentum

▼

Article image

On July 1, the 2023 Yangtze River Delta Jujin Sci-Tech Innovation Competition National Finals concluded successfully at Fudan University in Shanghai. Co-hosted by the Fudan University School of Management and the Shanghai Yangtze River Delta Business Innovation Institute by pooling high-quality domestic and international resources, the Yangtze River Delta Jujin Sci-Tech Innovation Competition is a professional competition for technology-based enterprises. It is dedicated to building an important platform for cultivating and connecting sci-tech enterprises, and to nurturing, incubating, and supporting the growth of innovative, cutting-edge, and breakthrough sci-tech projects.

As a technology company focused on clinical R&D, EClinCloud has consistently combined frontier technology with life data to build a globally leading "patient-centric" clinical evidence support SaaS cloud platform. Dr. Qin Long, founder and CEO of EClinCloud, entered this technology competition with EClinCloud's Clinical Evidence Support Cloud Platform project.

▼

Article image
The competition focused on hard-tech enterprises, bringing together highly innovative scientists and entrepreneurs from various fields to compete on the sci-tech innovation stage and showcase the strongest voice of China's sci-tech innovation. Over 20% of participants hold doctoral degrees, over 50% of the projects hold the designation of Technology-Based SME or High-Tech Enterprise, and 76% of the projects have secured Pre-A round financing or above. The participating projects were all driven by "hard tech": among the sci-tech enterprises in the preliminary round, each held an average of 10 technical patents; among the enterprises reaching the finals, each held an average of 17 technical patents, demonstrating a high degree of technological sophistication and representing the overall landscape and comprehensive standard of sci-tech innovation in the Yangtze River Delta and China as a whole.

▼

Article image

Focusing on key tracks including next-generation information technology, biomedicine, high-end manufacturing, new energy/new materials/energy conservation and environmental protection, and general technology sectors, the 2023 Yangtze River Delta Jujin Sci-Tech Innovation Competition spanned six months across four major competition regions—Jiangsu, Zhejiang, Shanghai, and Anhui. It attracted 253 project registrations. Through seven preliminary and semifinal rounds of rigorous screening, nearly 80 expert professors, investors, and sci-tech entrepreneurs participated in the review and exchange, and 156 teams advanced to the preliminary round.

▼

Article image
Article image
Article image
Article image
Article image

Swipe to view more

The Yangtze River Delta Jujin Sci-Tech Innovation Competition is more than just a contest;

it also stands for a spirit of self-reliance and innovative breakthroughs—
a microcosm of China's sci-tech innovation strength
Ultimately, the Yangtze River Delta Jujin Sci-Tech Innovation Competition selected 21 seed teams. Ahead of the national finals, a 3-day "Champion Challenge" boot camp provided finalist teams with comprehensive training in competition skills, including refining project content, polishing business plans, and improving roadshow presentation techniques. EClinCloud's Clinical Evidence Support Cloud Platform project ultimately won the Bronze Award.
Dr. Qin Long, CEO of EClinCloud, stated: "The Yangtze River Delta Jujin Sci-Tech Innovation Competition is a platform for all sci-tech innovation teams to showcase their dreams, and all the enterprises that reached the finals reflect the strongest force in China's sci-tech innovation. I am grateful to the competition for recognizing EClinCloud's project. Innovation goes beyond a single competition—the philosophy of scientific and technological innovation is deeply rooted in EClinCloud's development DNA. The Integrated Clinical Evidence Support SaaS Cloud Platform is an end-to-end, seamlessly integrated unified platform independently developed by EClinCloud. We hope to use the platform of this sci-tech innovation competition to connect more resources and rapidly reach across the industry, helping domestic and international pharmaceutical companies and research institutions accelerate new drug R&D, reduce clinical research costs, lower clinical research risks, and benefit more patients through EClinCloud's specialized solutions."

Article image



About EClinCloud

EClinCloud is a technology company focused on clinical R&D, offering an integrated, interconnected all-in-one clinical trial cloud platform (including solutions such as scale design, scale copyright management, linguistic validation, rater training, and data quality analysis across technology products and offerings such as eCOA, CTMS, eTMF, EDC, RTSM, and RM) as well as clinical trial endpoint assessment technologies across therapeutic areas (including central nervous system, ophthalmology, and others). By combining cutting-edge technology with life sciences data to build a globally leading, "patient-centric" SaaS cloud platform for clinical evidence support, it helps domestic and international pharmaceutical companies and research institutions improve R&D efficiency, accelerate drug/device launches, and benefit countless patients.




Article image


Read the original WeChat post

Related reading

WeChat image 2026-11-11_150855_109.pngNews6 min readWorld COPD Day | Imaging Assessment in COPD Clinical ResearchNovember 13-15, 2026. November 18, 2026 marks the 25 World COPD Day, with this year's theme: Early Diagnosis and Management for a Better Life. Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease characterized by persistent airflow limitation. COPD is closely related to chronic bronchitis and emphysema [1]. We have previously covered COAs for COPD,Article imageNews3 min readAddressing Complex Challenges in Clinical Research: EClinCloud’s Full-Lifecycle AI Enablement Attracts AttentionFrom November 13–15, the 2026 Nucleic Acid Therapy and Intelligent Biomedicine Industry Innovation Conference, academically guided by the Chinese Stroke Association and hosted by the Yuanshu Brain Science Research Center, was held in Fuzhou. Dr. Qin Long, founder and CEO of EClinCloud, was invited to deliver a keynote speech titled “Practice and Application of AI in Clinical Research,” sharing insights on the development trends of AI-enabled new drug R&D and the practice of AI throughout the clinical research process, which attracted enthusiastic attention from the attending guests. 01 Current Landscape of AI-Enabled New Drug R&D: AI is demonstrating application value in multiple segments of new drug R&D, including target discoverySAPA-China 2026 CNS Forum on-site photo 1News3 min readFocusing on CNS Clinical Endpoint Assessment: EClinCloud Shares eCOA and IRC PracticesAt the CNS Forum of the SAPA-China 2026 Pharmaceutical Industry Conference, Zheng Liangyan, Medical Director at EClinCloud, shared approaches to applying eCOA and IRC, covering challenges, regulatory requirements, and practical implementation in central nervous system (CNS) disease clinical research.